UCB syncs up with Roche and Genentech in Alzheimer’s drug deal worth a potential $2bn+
pharmafile | July 30, 2020 | News story | Research and Development, Sales and Marketing | Genentech, Roche, UCB, partnership
UCB Pharma is set to partner up with Roche and Genentech in a development and commercialisation deal focused on its drug candidate UCB0107, designed for the treatment of tauopathies such as progressive supranuclear palsy (PSP) and Alzheimer’s disease.
With this latest deal, Roche and Genentech want to push the candidate specifically as a treatment for Alzheimer’s disease and will make an upfront payment of $120 million to UCB, with up to $2 billion to follow contingent on the achievement of cost reimbursement, development and sales milestones. If commercially successful, UCB will also be entitled to receive royalty payments.
Kicking off the partnership, UCB will fund and run a proof-of-concept study for the drug in the treatment of Alzheimer’s to generate preliminary data. Based on this data, Genentech is eligible to then either assume development responsibilities or rescind the rights for the drug back to UCB.
So far, the drug has been shown to be safe and tolerable in healthy patients, according to data presented by UCB in September last year.
“In Alzheimer’s disease, we are continuing to explore new molecules that address the key pathways of this complex disease. We are pleased to embark on this journey together with UCB to help expand our efforts on tau,” explained James Sabry, Global Head of Roche Pharma Partnering. “Our commitment remains strong on exploring multiple approaches with the hope that our research and development, including this collaboration with UCB, will lead to a disease-modifying medicine that could positively impact millions of people with Alzheimer’s disease.”
Matt Fellows
Related Content
UCB presents positive results for fenfluramine in CDKL5 deficiency disorder
UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …
Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies
Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …
UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …
